## **Supplemental Online Content**


Tsai SHL, Hu CW, El Sammak S, et al. Different gabapentin and pregabalin dosages for perioperative pain control in patients undergoing spine surgery: a systematic review and network meta-analysis. *JAMA Netw Open.* 2023;6(8):e2328121. doi:10.1001/jamanetworkopen.2023.28121

- eFigure 1. Network Graph for Vomit and Dizziness
- eFigure 2. Risk of Bias Assessment of the Included Studies
- eFigure 3. Network Meta-Analysis League Tables
- eFigure 4. Rank Plot
- **eFigure 5.** Forest Plot of Network Meta-Analysis Results (Placebo as Reference)
- eFigure 6. Forest Plot of Pairwise Comparison for Each Outcome
- eFigure 7. Publication Bias: Funnel Plot
- **eFigure 8.** Publication Bias: The Egger Test
- eFigure 9. CINeMA for the Perioperative Outcomes (VAS, Opioid Consumption, Nausea, Vomit, Dizziness)
- eTable 1. Electronic Database Search Strategy
- eTable 2. Excluded Studies With Reasons
- eTable 3. Descriptions and Demo of the Included Studies
- eTable 4. Assessment of Inconsistency With Design-by-Treatment Interaction Models
- **eTable 5.** Meta-Regression of Covariates for Outcomes
- **eTable 6.** SUCRA, PrBest, and Mean Rank of Different Dosages of Gabapentin and Pregabalin for Patients Undergoing Spinal Surgery
- eFigure 10. Network Graph for Nausea Without Funding
- eFigure 11. Network Meta-Analysis League Tables for Nausea Without Funding
- eFigure 12. Rank Plot for Nausea Without Funding
- **eFigure 13.** Forest Plot of Network Meta-Analysis Results for Nausea Without Funding (Placebo as Reference)
- eFigure 14. Forest Plot of Pairwise Comparison for Nausea Without Funding
- eFigure 15. Publication Bias: Funnel Plot for Nausea Without Funding
- eFigure 16. Publication Bias: The Egger Test for Nausea Without Funding
- eFigure 17. CINeMA for Nausea Without Funding
- **eTable 7.** SUCRA, PrBest, and Mean Rank of Different Dosages of Gabapentin and Pregabalin for Patients Undergoing Spinal Surgery
- eTable 8. Assessment of Inconsistency With Design-by-Treatment Interaction Models
- **eReferences**


This supplemental material has been provided by the authors to give readers additional information about their work.

### eFigure 1: Network Graph for Vvomit and Dizziness

\* The sizes of the nodes are proportional to the included cases randomized to the treatments, and the number on the lines indicate the number of studies comparing two nodes.



eFigure 2 Risk of Bias Assessment of the Included Studies



	Random sequence generation (selection bias)	4 Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Altiparmak 2018	•		•	•		•	?
Bala 2019	•	•	?	?	•	•	?
Baloch 2021	?	•	•	•	•	•	?
Burke 2010	•	•	•	?	+	•	?
Choi 2013	•	•	•	•	•	•	?
Glanesello 2012	•	•	•	•	•	•	?
Hegarty 2011	•	•	•	•	•	•	?
Khan 2011	•	?	•	•	•	•	?
Khurana 2014	•	•	?	•	•	•	?
Klen 2019	•	•	?	?	•	•	?
Kim 2011	•	•	•	•	•	•	?
Kumar 2013 Momon 2019	<b>+</b>	<b>+</b>	•	<b>+</b>	<b>+</b>	<b>+</b>	?
Ozgencii 2011	•	•	?	?	•	•	?
Pandey 2004	•	•	•	•	•	•	?
Pandey 2005	•	?	•	•	•	•	?
Qadeer 2017	•	•	?	?	•	•	?
Radhakrishnan 2005	•	•	•	•	•	•	?
Raja 2019	•	•	?	•	•	•	?
Routray 2018	•	•	?	?	+	•	?
Spreng 2011	•	?	•	?	+	•	?
Turan 2004	•	•	•	•	•	•	?
Urban 2018	•	?	•	•	•	•	?
Vasigh 2016	•	•	•	•	+	•	?
Yadav 2018	•	?	•	•	•	•	?
Zarei 2016	•	?	•	•	•	•	?
Zhang 2021	•	•	?	?	•	•	?

## **eFigure 3:** Network Meta-Analysis League Tables

(Comparisons between treatments (column vs row) should be read from left to right and the order of the treatments in the diagonal doesn't reflect ranking)

## (\*: Significant difference)

**A:** Network meta-analysis league tables for postoperative pain intensity (VAS) (In the left lower half, mean differences lower than 0 favor the row-defining treatment)

Placebo									
*1.64	Gabapentin								
(0.42, 2.86)	300mg								
0.94	-0.70	Gabapentin							
(-0.90,2.78)	(-2.91,1.50)	400mg							
*2.11	0.47	1.17	Gabapentin						
(1.12,3.10)	(-0.93,1.87)	(-0.91,3.26)	600mg						
0.00	-1.64	-0.94	-2.11	Gabapentin					
(-3.27,3.27)	(-5.14,1.85)	(-4.69,2.82)	(-5.53,1.31)	800mg		_			
*2.67	1.03	1.74	0.56	2.67	Gabapentin				
(1.54,3.80)	(-0.41,2.47)	(-0.42,3.89)	(-0.66,1.79)	(-0.79,6.14)	900mg				
*2.49	0.84	1.55	0.38	2.49	-0.19	Gabapentin			
(1.58,3.39)	(-0.51,2.20)	(-0.50,3.60)	(-0.75,1.50)	(-0.91,5.88)	(-1.37,1.00)	1200mg			
0.94	-0.70	0.00	-1.17	0.94	-1.73	-1.55	Pregabalin		
(-0.05,1.93)	(-2.27,0.87)	(-2.05,2.05)	(-2.57,0.23)	(-2.48,4.36)	(-3.24,-0.23)	(-2.89,-0.21)	75mg		
*1.31	-0.33	0.37	-0.80	1.31	-1.37	-1.18	0.37	Pregabalin	
(0.6, 1.99)	(-1.73,1.07)	(-1.34,2.08)	(-2.00,0.40)	(-2.04,4.65)	(-2.69,-0.04)	(-2.31,-0.05)	(-0.77,1.50)	150mg	
*1.41	-0.23	0.47	-0.70	1.41	-1.26	-1.08	0.47	0.10	Pregabalin
(0.41, 2.41)	(-1.78,1.31)	(-1.62,2.56)	(-2.06,0.66)	(-2.01,4.83)	(-2.72,0.19)	(-2.28,0.13)	(-0.93,1.88)	(-1.10,1.31)	300mg

**B:** Network meta-analytic relative treatment effects for opioid consumption (In the left lower half, mean differences lower than 0 favor the row-defining treatment)

Placebo								
-4.24	Gabapentin							
(-15.87,7.40)	300mg	~	1					
*-15.25	-11.01	Gabapentin						
(-23.48,-7.02)	(-23.93,1.91)	600mg						
0.40	4.64	15.65	Gabapentin					
(-17.56,18.36)	(-16.76,26.03)	(-4.11,35.41)	800mg		_			
*-22.07	*-17.83	-6.82	*-22.47	Gabapentin				
(-33.22,-10.92)	(-32.11,-3.56)	(-18.44,4.80)	(-43.61,-1.33)	900mg		_		
*-20.36	*-16.13	-5.12	*-20.76	1.70	Gabapentin			
(-28.80,-11.93)	(-29.18,-3.08)	(-15.13,4.90)	(-40.61,-0.92)	(-10.02,13.43)	1200mg			
-1.92	2.32	13.33	-2.32	20.15	18.44	Pregabalin		
(-19.27,15.43)	(-18.57,23.20)	(-5.87,32.53)	(-27.29,22.65)	(-0.47,40.77)	(-0.85,37.73)	75mg		_
*-9.33	-5.09	5.92	-9.73	12.74	11.04	-7.41	Pregabalin	
(-17.90,-0.75)	(-19.47,9.28)	(-5.77,17.61)	(-29.63,10.17)	(-1.19,26.67)	(-0.79,22.87)	(-26.76,11.94)	150mg	
*-13.60	-9.37	1.64	-14.00	8.46	6.76	-11.68	-4.28	Pregabalin
(-21.74,-5.47)	(-23.21,4.47)	(-8.84,12.12)	(-33.72,5.71)	(-4.76,21.68)	(-3.88,17.40)	(-30.85,7.48)	(-15.19,6.63)	300mg

C: Network meta-analytic relative treatment effects for Nausea (In the left lower half, odds ratio lower than 1 favor the row-defining treatment)

Placebo			C					
0.57	Gabapentin							
(0.17, 1.85)	300mg							
0.57	1.01	Gabapentin						
(0.23,1.41)	(0.24,4.31)	600mg						
1.00	1.76	1.74	Gabapentin					
(0.22,4.63)	(0.25, 12.19)	(0.29,10.27)	800mg					
0.66	1.16	1.15	0.66	Gabapentin				
(0.16, 2.72)	(0.19, 6.97)	(0.27,4.90)	(0.08, 5.31)	900mg				
0.95	1.68	1.66	0.95	1.45	Gabapentin			
(0.41, 2.19)	(0.41, 6.85)	(0.55,4.98)	(0.17, 5.46)	(0.33,6.30)	1200mg			
0.88	1.55	1.53	0.88	1.34	0.92	Pregabalin		
(0.39, 2.00)	(0.42, 5.70)	(0.47, 5.05)	(0.15, 5.02)	(0.26,6.76)	(0.29, 2.95)	75mg		
*0.41	0.72	0.71	0.41	0.62	0.43	0.46	Pregabalin	
(0.17, 0.98)	(0.17, 3.09)	(0.20,2.47)	(0.07, 2.39)	(0.12,3.26)	(0.13,1.43)	(0.15,1.46)	150mg	
0.57	1.01	0.99	0.57	0.87	0.60	0.65	1.40	Pregabalin
(0.27,1.21)	(0.25, 4.05)	(0.33,2.99)	(0.10, 3.16)	0.18,4.14)	(0.22,1.65)	(0.21,1.98)	(0.44, 4.47)	300mg

**D:** Network meta-analytic relative treatment effects for Vomit (In the left lower half, odds ratio lower than 1 favor the row-defining treatment)


Placebo			C					
0.87	Gabapentin							
(0.32, 2.41)	300mg							
*0.47	0.53	Gabapentin						
(0.22, 0.99)	(0.16, 1.76)	600mg						
0.64	0.74	1.38	Gabapentin					
(0.10,4.15)	(0.09, 6.15)	(0.18, 10.30)	800mg					
0.35	0.40	0.74	0.54	Gabapentin				
(0.07, 1.73)	(0.07, 2.39)	(0.15, 3.78)	(0.05, 6.33)	900mg		_		
0.45	0.51	0.96	0.70	1.30	Gabapentin			
(0.18,1.13)	(0.14, 1.86)	(0.33, 2.83)	(0.09, 5.61)	(0.24, 7.08)	1200mg			
0.58	0.66	1.24	0.90	1.67	1.29	Pregabalin		
(0.22, 1.52)	(0.17, 2.61)	(0.37,4.20)	(0.11,7.35)	(0.26, 10.83)	(0.34,4.87)	75mg		
0.39	0.44	0.83	0.60	1.12	0.86	0.67	Pregabalin	
(0.14,1.11)	(0.10, 1.91)	(0.23, 3.02)	(0.07, 5.12)	(0.16, 7.62)	(0.21,3.48)	(0.16, 2.78)	150mg	
0.57	0.65	1.22	0.89	1.65	1.27	0.99	1.47	Pregabalin
(0.30,1.10)	(0.20, 2.15)	(0.49, 3.07)	(0.12,6.41)	(0.30, 9.06)	(0.44, 3.64)	(0.31, 3.15)	(0.43, 5.09)	300mg

**E:** Network meta-analytic relative treatment effects for Dizziness (In the left lower half, odds ratio lower than 1 favor the row-defining treatment)


Placebo							
0.32	Gabapentin						
(0.01, 8.24)	300mg						
1.52	4.72	Gabapentin					
(0.70,3.30)	(0.17,132.59)	600mg					
1.17	3.65	0.77	Gabapentin				
(0.17,8.31)	(0.08,161.20)	(0.10,6.05)	900mg		_		
1.66	5.17	1.10	1.42	Gabapentin			
(0.77, 3.62)	(0.18,145.26)	(0.38, 3.13)	(0.20, 9.88)	1200mg			
1.95	6.05	1.28	1.66	1.17	Pregabalin		
(0.43, 8.86)	(0.17,217.05)	(0.23, 7.04)	(0.14, 19.72)	(0.21, 6.42)	75mg		
0.85	2.66	0.56	0.73	0.51	0.44	Pregabalin	
(0.21, 3.42)	(0.08,90.42)	(0.11,2.76)	(0.07, 8.02)	(0.10, 2.51)	(0.09, 2.13)	150mg	
1.12	3.48	0.74	0.96	0.67	0.58	1.31	Pregabalin
(0.57, 2.19)	(0.13,95.59)	(0.29, 1.88)	(0.13, 7.24)	(0.28, 1.61)	(0.11,3.02)	(0.28,6.11)	300mg

## eFigure 4: Rank Plot

### A: VAS




### C: Nausea




© 2023 Tsai SHL et al. JAMA Network Open.


## **B: Opioid consumption**



### D: Vomit




## E: Dizziness




**eFigure 5:** Forest Plot of Network Meta-Analysis Results (Placebo as Reference)


### A: VAS




## **B:** Opioid consumption




### C: Nausea



### D: Vomit




### E: Dizziness



eFigure 6: Forest Plot of Pairwise Comparison for Each Outcome

**eFigure 6a:** VAS: (A: placebo, B: Gabapentin 300mg, C: Gabapentin 400mg, D: Gabapentin 600 mg, E: Gabapentin 800mg, F: Gabapentin 900mg, G: Gabapentin 1200mg, H: pregabalin 75mg, I: pregabalin 150mg J: pregabalin 300mg)




eFigure 6b: Opioid consumption

# (A: placebo, B: Gabapentin 300mg, C: Gabapentin 600 mg, D: Gabapentin 800mg, E: Gabapentin 900mg F: Gabapentin 1200mg, G: pregabalin 75mg, H: pregabalin 150mg, I: pregabalin 300mg)

Baseline Other study treatment treatment	WMD (95% CI)	% Weight
B-A 1 A B	-8.40 (-12.75, -4.05)	55.58
3 A B	-15.84 (-22.37, -9.31)	44.42
Subtotal (I-squared = 71.1%, p = 0.063)	-11.71 (-18.95, -4.46)	100.00
F - A 2 A F	26 50 / 22 02 - 20 09)	25.01
2 A F — — — — — — — — — — — — — — — — — —	-26.50 (-32.02, -20.98) -39.90 (-47.19, -32.61)	24.12
5 A F	-12.90 (-17.04, -8.76)	25.57
6 A F Subtotal (I-squared = 95.5%, p = 0.000)	-7.86 (-12.70, -3.02) -21.54 (-33.91, -9.16)	25.30 100.00
C - A		
3 A C	-34.87 (-41.20, -28.54)	22.43
5 A C C	-6.50 (-10.45, -2.55)	24.81 26.38
15 A C	-18.20 (-19.61, -16.79) -9.02 (-10.44, -7.60)	26.38
Subtotal (I-squared = 97.8%, p = 0.000)	-16.61 (-24.16, -9.07)	100.00
E-A	00.04 / 40.00 00.45	40.40
3 A E E	-39.34 (-46.23, -32.45) -12.30 (-16.21, -8.39)	49.43 50.57
Subtotal (I-squared = 97.8%, p = 0.000)	-25.67 (-52.16, 0.83)	100.00
C - B		
3 B C Subtotal (I-squared = .%, p = .)	-19.03 (-24.14, -13.92) -19.03 (-24.14, -13.92)	100.00 100.00
	-13.00 (*27.17, -10.32)	100.00
E-B 3 B E	-23.50 (-29.29, -17.71)	100.00
Subtotal (I-squared = .%, p = .)	-23.50 (-29.29, -17.71)	100.00
F-B 3 B F	-24.06 (-30.32, -17.80)	100.00
Subtotal (I-squared = .%, p = .)	-24.06 (-30.32, -17.80) -24.06 (-30.32, -17.80)	100.00
E - C		
3 C E	-4.47 (-10.03, 1.09)	7.74
5 C E Subtotal (I-squared = 0.0%, p = 0.653)	-5.80 (-7.41, -4.19) -5.70 (-7.24, -4.15)	92.26 100.00
F-C		
3 C F	-5.03 (-11.08, 1.02)	10.84
5 C F Subtotal (I-squared = 0.0%, p = 0.675)	-6.40 (-8.51, -4.29) -6.25 (-8.24, -4.26)	89.16 100.00
F-E		
3 E F <b>-</b>	-0.56 (-7.19, 6.07)	8.51
5 E F Subtotal (I-squared = 0.0%, p = 0.991)	-0.60 (-2.62, 1.42) -0.60 (-2.53, 1.34)	91.49 100.00
D-A	I	
4 A D	0.40 (-4.37, 5.17)	100.00
Subtotal (I-squared = .%, p = .)	0.40 (-4.37, 5.17)	100.00
I-A 6 A I	-11.00 (-15.78, -6.22)	22.22
7 Å İ	-6.50 (-7.65, -5.35)	26.43
10 A I 15 A I	-9.88 (-12.66, -7.10)	25.03 26.32
Subtotal (I-squared = 97.1%, p = 0.000)	-15.60 (-16.95, -14.25) -10.74 (-16.23, -5.25)	100.00
I-F		
6 F I Subtotal (I-squared = .%, p = .)	-3.14 (-7.96, 1.68) -3.14 (-7.96, 1.68)	100.00 100.00
	-0.14 (-7.30, 1.00)	100.00
H-A 8 A H	-0.43 (-1.35, 0.49)	26.98
10 A H	-8.40 (-12.50, -4.30)	24.11
11 A H 13 A H	-7.00 (-12.10, -1.90) -55.33 (-86.23, -24.43)	22.72 3.33
14 A H	-8.03 (-13.04, -3.02)	22.86
8 A H 10 A H 11 A H 13 A H 14 A H Subtotal (I-squared = 89.6%, p = 0.000)	-7.41 (-13.43, -1.39)	100.00
I-H	-1.48 (-5.04, 2.08)	100.00
10 H I Subtotal (I-squared = .%, p = .)	-1.48 (-5.04, 2.08)	100.00
G-A		
12 A G Subtotal (I-squared = .%, p = .)	-1.92 (-3.00, -0.84) -1.92 (-3.00, -0.84)	100.00 100.00
I-C	( , ,	. 55,55
15 C I ♦	-6.58 (-7.26, -5.90)	100.00
Subtotal (I-squared = .%, p = .)	-6.58 (-7.26, -5.90)	100.00
NOTE: Weights are from random effects analysis		


eFigure 6c: Nausea

(A: placebo, B: Gabapentin 300mg, C: Gabapentin 600 mg, D: Gabapentin 800mg, E: Gabapentin 900mg, F: Gabapentin 1200mg, G: pregabalin 75mg, H: pregabalin 150mg, I: pregabalin 300mg)




© 2023 Tsai SHL et al. JAMA Network Open.

eFigure 6d: Vomit (A: placebo, B: Gabapentin 300mg, C: Gabapentin 600 mg, D: Gabapentin 800mg, E: Gabapentin 900mg, F:




(A: placebo, B: Gabapentin 300mg, C: Gabapentin 600 mg, D: Gabapentin 900mg, E: Gabapentin 1200mg, F: pregabalin 75mg, G: pregabalin 150mg, H: pregabalin 300mg)




eFigure 7: Publication Bias Funnel Plot


### A: VAS




## **B:** Opioid consumption




### C: Nausea



### D: Vomit




## E: Dizziness




**eFigure 8:** Publication Bias: The Egger Test


## A: VAS




## **B: Opioid consumption**




C: Nausea



### D: Vomit



## E: Dizziness



### eFigure 9: CINeMA for the Perioperative Outcomes (VAS, Opioid Consumption, Nausea, Vomit, Dizziness)

Study limitations (Within study bias): ROB (Cochrane risk-of-bias tool for randomized trials) was assessed and "Average Risk of Bias" was implemented in CINeMA to calculate the within study bias.

**Publication bias (Across studies bias)**: Since p value was < 0.05 from Egger test and no obvious asymmetry was noticed in funnel plot, "all at low risk" was set in CINeMA.

**Indirectness:** we can assume all studies in our analysis had similar distribution in terms of their study population (spinal surgery), intervention (gabapentin/pregabalin) and outcome assessments (VAS, morphine, nausea, etc.) Thus, we judged that there was no serious concern in this domain.

**Imprecision:** In CINeMA setting, we considered a clinically meaningful threshold for mean difference (MD) to be 1 for VAS <sup>1</sup>, and 10mg IV morphine for opioid consumption due to its most common IV form dosage and our analysis showing that the least significant morphine consumption is around 10 mg (Supplementary Figure 5B). Similarly, odds ratio as clinically importance was set to 0.4 for nausea, vomit and dizziness.

**Heterogeneity:** According to CINeMA system, heterogeneity was evaluated through comparing the clinical inference based on the 95% confidence intervals (CI) and 95% prediction interval (PI). <sup>2</sup>

**Incoherence** (**Inconsistency**): For inconsistency design-by-treatment interaction model was implemented. There was no significance for overall analysis with P>0.05 while some concerns or major concerns were noted in pair wise comparisons.

eFigure 9A: CINeMA for VAS

			Mixed e	vidence				
Gabapentin1200 vs Gabapentin300	1	Some concerns □	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin1200 vs Gabapentin600	2	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	Major concerns 🗆	Very low 🗸
Gabapentin1200 vs Gabapentin900	2	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	Major concerns 🗆	Very low 🗸
Gabapentin1200 vs Placebo	4	Some concerns 🗆	Low risk	No concerns	No concerns	No concerns	No concerns	Moderate <b>∨</b>
Gabapentin1200 vs Pregabalin300	1	Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin300 vs Gabapentin600	1	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin300 vs Gabapentin900	1	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin300 vs Placebo	2	Some concerns	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
Gabapentin400 vs Pregabalin150	1	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Low
Gabapentin600 vs Gabapentin900	2	Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin600 vs Placebo	3	Some concerns	Low risk	No concerns	No concerns	No concerns	No concerns	Moderate <b>∨</b>
Gabapentin800 vs Placebo	1	No concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Low
Gabapentin900 vs Placebo	2	Some concerns □	Low risk	No concerns	No concerns	No concerns	No concerns	Moderate <b>✓</b>
Placebo vs Pregabalin150	7	Some concerns □	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
Placebo vs Pregabalin300	4	Some concerns □	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
Placebo vs Pregabalin75	3	No concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Moderate <b>∨</b>
Pregabalin150 vs Pregabalin75	1	No concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Moderate <b>∨</b>

		Indirect	evidence				
Gabapentin1200 vs Gabapentin400	 Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	Some concerns □	No concerns	Low
Gabapentin1200 vs Gabapentin800	 Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	No concerns	Modera
Gabapentin1200 vs Pregabalin150	 Some concerns 🗆	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
abapentin1200 vs Pregabalin75	 Some concerns 🗆	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
abapentin300 vs Gabapentin400	 Some concerns 🗆	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very lo
abapentin300 vs Gabapentin800	 No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low
Gabapentin300 vs Pregabalin150	 Some concerns 🗆	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low
Gabapentin300 vs Pregabalin300	 Some concerns 🗆	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very lo
Gabapentin300 vs Pregabalin75	 Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin400 vs Gabapentin600	 Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin400 vs Gabapentin800	 Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	High
Gabapentin400 vs Gabapentin900	 Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	Some concerns □	No concerns	Low
Gabapentin400 vs Placebo	 Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin400 vs Pregabalin300	 Some concerns 🗆	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low
Gabapentin400 vs Pregabalin75	 Some concerns 🗆	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very lo
Gabapentin600 vs Gabapentin800	 No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low
abapentin600 vs Pregabalin150	 Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns 🗆	No concerns	Low
abapentin600 vs Pregabalin300	 Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low

@ 2023 Tsai SHL et al.  $\emph{JAMA Network Open}.$ 

Gabapentin600 vs Pregabalin75	Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin800 vs Gabapentin900	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns □	No concerns	Low 🗸
Gabapentin800 vs Pregabalin150	No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low 🗸
Gabapentin800 vs Pregabalin300	No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low 🗸
Gabapentin800 vs Pregabalin75	No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low 🗸
Gabapentin900 vs Pregabalin150	Some concerns 🗆	Low risk	No concerns	No concerns	Some concerns □	No concerns	Low 🗸
Gabapentin900 vs Pregabalin300	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low 🗸
Gabapentin900 vs Pregabalin75	Some concerns	Low risk	No concerns	No concerns	Some concerns □	No concerns	Low 🗸
Pregabalin150 vs Pregabalin300	Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very low 🗸
Pregabalin300 vs Pregabalin75	Some concerns 🗆	Low risk	No concerns	Some concerns □	Some concerns □	No concerns	Low 🗸

eFigure 9B CINeMA for opioid consumption

Comparison	Number of Studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
			Mixed	evidence				
Gabapentin1200 vs Gabapentin300	1	Some concerns □	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
Gabapentin1200 vs Gabapentin600	2	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin1200 vs Gabapentin900	2	Some concerns	Lowrisk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin1200 vs Placebo	4	Some concerns □	Lowrisk	No concerns	No concerns	No concerns	No concerns	Moderate <b>✓</b>
Gabapentin1200 vs Pregabalin300	1	Some concerns □	Lowrisk	No concerns	Some concerns 🗆	Some concerns	No concerns	Low
Gabapentin300 vs Gabapentin600	1	Some concerns □	Low risk	No concerns	Some concerns 🗆	No concerns	No concerns	Low
Gabapentin300 vs Gabapentin900	1	Some concerns	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
Gabapentin300 vs Placebo	2	Some concerns □	Low risk	No concerns	Some concerns	Some concerns	Ministerioris 🗖	Very low 🗸
Gabapentin600 vs Gabapentin900	2	Some concerns □	Lowrisk	No concerns	Some concerns □	Some concerns	No concerns	Low
Gabapentin600 vs Placebo	4	Some concerns □	Lowrisk	No concerns	No concerns	Some concerns □	No concerns	Low
Gabapentin600 vs Pregabalin300	1	Some concerns □	Lowrisk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin800 vs Placebo	1	No concerns	Low risk	No concerns	Индерсийный и	No concerns	Major commonted.	Very low 💙
Gabapentin900 vs Placebo	2	Some concerns □	Low risk	No concerns	No concerns	No concerns	No concerns	Moderate <b>▽</b>
Placebo vs Pregabalin150	5	Some concerns □	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
Placebo vs Pregabalin300	4	Some concerns □	Lowrisk	No concerns	No concerns	Some concerns	Some concerns	Very low 🗸
Placebo vs Pregabalin75	1	Some concerns □	Lowrisk	No concerns	Miller on draft	No concerns	Administrative	Very low 🗸
Pregabalin150 vs Pregabalin300	1	Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low

@ 2023 Tsai SHL et al.  $\emph{JAMA Network Open}.$ 

		Indirect	evidence				
Gabapentin1200 vs Gabapentin800	No concerns	Low risk	No concerns	No concerns	Some concerns	Major concerns	Very low 💙
Gabapentin1200 vs Pregabalin150	Some concerns	Low risk	No concerns	No concerns	Some concerns	Major concerns 🗖	Very low 🗸
Gabapentin1200 vs Pregabalin75	Some concerns	Low risk	No concerns	No concerns	Some concerns	Major concerns 🗉	Very low 💙
Gabapentin 300 vs Gabapentin 800	No concerns	Low risk	No concerns	Major concerns 🗷	No concerns	Major concerns 🗉	Very low 🗸
Gabapentin300 vs Pregabalin150	Some concerns	Low risk	No concerns	Some concerns □	Some concerns	Major concerns 🗆	Very low 💙
Gabapentin300 vs Pregabalin300	Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	Some concerns	Major concerns 🗆	Very low 🗸
Gabapentin300 vs Pregabalin75	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns	Major concerns 🗆	Very low 💙
Gabapentin600 vs Gabapentin800	No concerns	Low risk	No concerns	Some concerns □	No concerns	Major concerns 🗆	Very low 💙
Gabapentin600 vs Pregabalin150	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns 🗆	Major concerns 🗖	Very low 🗸
Gabapentin600 vs Pregabalin75	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns 🗆	Major concerns 🗖	Very low 🗸
Gabapentin800 vs Gabapentin900	Some concerns	Low risk	No concerns	No concerns	Some concerns	Major concerns 🗆	Very low 🕶
Gabapentin800 vs Pregabalin150	No concerns	Low risk	No concerns	Some concerns	Some concerns 🗆	Major concerns 🗆	Very low 🗸
Gabapentin800 vs Pregabalin300	No concerns	Low risk	No concerns	Some concerns	Some concerns 🗆	Major concerns 🗖	Very low 🗸
Gabapentin800 vs Pregabalin75	Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	Major concerns 🗆	Very low 🗸
Gabapentin900 vs Pregabalin150	Some concerns 🗆	Low risk	No concerns	No concerns	Some concerns 🗆	Major concerns 🗆	Very low 🕶
Gabapentin900 vs Pregabalin300	Some concerns 🗆	Low risk	No concerns	Some concerns	Some concerns	Major concerns 🗖	Very low 🗸
Gabapentin900 vs Pregabalin75	Some concerns	Low risk	No concerns	No concerns	Some concerns	Major concerns 🗖	Very low 🕶
Pregabalin150 vs Pregabalin75	Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	Some concerns	Major concerns 🗆	Very low 🕶
Pregabalin300 vs Pregabalin75	Some concerns	Low risk	No concerns	Some concerns	Some concerns	Major concerns 🗉	Very low 🗸

@ 2023 Tsai SHL et al.  $\emph{JAMA Network Open}.$ 

eFigure 9C: CINeMA for Nausea

Comparison	Number of Studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
			Mixed evi	dence				
Gabapentin1200 vs Gabapentin300	1	Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Low
Gabapentin1200 vs Gabapentin600	2	Some concerns 🗆	Low risk	No concerns	Some concerns	No concerns	No concerns	Low
Gabapentin1200 vs Gabapentin900	2	Some concerns 🗆	Low risk	No concerns	Major community 🗷	No concerns	No concerns	Very low
Gabapentin1200 vs Placebo	4	Some concerns	Lowrisk	No concerns	No concerns	Major consums	No concerns	Very low
Gabapentin1200 vs Pregabalin300	1	Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	No concerns	No concerns	Low
Gabapentin300 vs Gabapentin600	1	Some concerns 🗆	Low risk	No concerns	Water concerns	No concerns	No concerns	Very low `
Gabapentin300 vs Gabapentin900	1	Some concerns	Low risk	No concerns	Water conserve	No concerns	No concerns	Very low
Gabapentin300 vs Placebo	3	No concerns	Low risk		Some concerns □	No concerns	No concerns	Moderate *
Gabapentin300 vs Pregabalin75	1	Some concerns 🗆	Lowrisk	No concerns	Some concerns □	Some concerns 🗆	No concerns	Low
Gabapentin600 vs Gabapentin900	2	Some concerns	Lowrisk	No concerns	Make contains	No concerns	No concerns	Very low *
Gabapentin600 vs Placebo	4	Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	No concerns	No concerns	Low
Gabapentin600 vs Pregabalin300	1	Some concerns 🗆	Low risk	No concerns	Major communic	No concerns	No concerns	Very low
Gabapentin800 vs Placebo	1	No concerns	Low risk	No concerns	former commons =	No concerns	No concerns	Very low
Gabapentin900 vs Placebo	2	Some concerns	Low risk	No concerns	Some concerns	Some concerns 🗆	No concerns	Low
Placebo vs Pregabalin150	5	Some concerns 🗆	Low risk	No concerns	No concerns	Some concerns 🗆	No concerns	Low
Placebo vs Pregabalin300	6	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Low
Placebo vs Pregabalin75	4	Some concerns 🗆	Low risk	No concerns	No concerns	Some concerns 🗆	No concerns	Low
Pregabalin150 vs Pregabalin75	1	Some concerns	Lowrisk		Some concerns	No concerns	No concerns	Low

<sup>@</sup> 2023 Tsai SHL et al.  $\emph{JAMA Network Open}.$ 

			Indirect evid	dence			
Gabapentin1200 vs Gabapentin800	-75	No concerns	Low risk	No concerns	(Majories mention)	No concerns	No concerns
Sabapentin1200 vs Pregabalin150	S#5	Some concerns 🗆	Lowrisk	No concerns	Some concerns 🗆	No concerns	No concerns
abapentin1200 vs Pregabalin75		Some concerns	Low risk	No concerns	/Majores on envoyed	No concerns	No concerns
bapentin300 vs Gabapentin800	**	No concerns	Low risk	No concerns	Андинестичност	No concerns	No concerns
abapentin300 vs Pregabalin150	**	Some concerns	Low risk		MARKO CONTRACTOR	No concerns	No concerns
abapentin300 vs Pregabalin300	24	Some concerns	Low risk	No concerns	Минанаоневите	No concerns	No concerns
abapentin600 vs Gabapentin800	200	No concerns	Low risk	No concerns	Минакаоначиты.	No concerns	No concerns
abapentin600 vs Pregabalin150	141	Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	Some concerns 🗆	No concerns
bapentin600 vs Pregabalin75	-A1;	Some concerns 🗆	Lowrisk		Some concerns	No concerns	No concerns
bapentin800 vs Gabapentin900	and the same of th	Some concerns	Low risk		Malapannenska	No concerns	No concerns
bapentin800 vs Pregabalin150	**	No concerns	Lowrisk	No concerns	Some concerns	No concerns	No concerns
bapentin800 vs Pregabalin300	-75	No concerns	Low risk	No concerns	Management (4)	No concerns	No concerns
abapentin800 vs Pregabalin75	-Ti-	No concerns	Low risk	No concerns	Manage content of the	No concerns	No concerns
abapentin900 vs Pregabalin150	Sto	Some concerns	Lowrisk		Manusconcerns.	No concerns	No concerns
abapentin900 vs Pregabalin300	-	Some concerns	Low risk	No concerns	Managaran	No concerns	No concerns
abapentin900 vs Pregabalin75	-	Some concerns	Low risk	No concems	Management	No concerns	No concerns
regabalin150 vs Pregabalin300	**	Some concerns 🗆	Low risk		Some concerns 🗆	Some concerns -	No concerns
regabalin300 vs Pregabalin75	24	Some concerns	Low risk	No concems	Some concerns	No concerns	No concerns

@ 2023 Tsai SHL et al.  $\emph{JAMA Network Open}.$ 

eFigure 9D: CINeMA for Vomit

Comparison	Number of Studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
			Mixed evid	dence				
Gabapentin1200 vs Gabapentin300	1	Some concerns	Low risk	No concerns	Some concerns 🗆	No concerns	No concerns	Low 🗸
Gabapentin1200 vs Gabapentin600	2	Some concerns 🗆	Low risk	No concerns	Mbgor community	No concerns	No concerns	Very low 🗸
Gabapentin1200 vs Gabapentin900	2	Some concerns	Low risk	No concerns	Majoreametine	No concerns	No concerns	Very low 🗸
Gabapentin1200 vs Placebo	4	Some concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Low
Gabapentin1200 vs Pregabalin300	1	Some concerns	Low risk	No concerns	Some concerns 🗆	No concerns	No concerns	Low
Gabapentin300 vs Gabapentin600	1	Some concerns	Low risk	No concerns	Some concerns 🗆	No concerns	No concerns	Low
Gabapentin300 vs Gabapentin900	1	Some concerns □	Low risk	No concerns	Some concerns	Some concerns 🗆	No concerns	Low
Gabapentin300 vs Placebo	3	Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	Some concerns	No concerns	Low
Gabapentin300 vs Pregabalin75	1	Some concerns	Low risk	No concerns	Major community -	No concerns	No concerns	Very low 🗸
Gabapentin600 vs Gabapentin900	2	Some concerns	Low risk	No concerns	linates community =	No concerns	No concerns	Very low 🗸
Gabapentin600 vs Placebo	4	Some concerns	Low risk	No concerns	No concerns	Some concerns	No concerns	Low
Gabapentin600 vs Pregabalin300	1	Some concerns	Low risk	No concerns	Some concerns 🗆	No concerns	No concerns	Low
Gabapentin800 vs Placebo	1	No concerns	Łow risk	No concerns	Missien som sennt:	No concerns	No concerns	Low
Gabapentin900 vs Placebo	2	Some concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Low
Placebo vs Pregabalin150	4	Some concerns	Low risk		Some concerns	No concerns	No concerns	Low
Placebo vs Pregabalin300	6	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate ➤
Placebo vs Pregabalin75	3	Some concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Low

			Indirect evi	dence				
Gabapentin1200 vs Gabapentin800	286	No concerns	Low risk	No concerns	Mana semanana.	No concerns	No concerns	Low
Gabapentin1200 vs Pregabalin150	286	Some concerns	Low risk	No concerns	Manus sources (in a	No concerns	No concerns	Low
Gabapentin1200 vs Pregabalin75		Some concerns	Low risk	No concerns	More reconstruct	No concerns	No concerns	Very low
Gabapentin300 vs Gabapentin800	-	No concerns	Lowrisk	No concerns	///www.same#me/■	No concerns	No concerns	Low
Gabapentin300 vs Pregabalin150		Some concerns	Lowrisk	No concerns	Some concerns	No concerns	No concerns	Low
Gabapentin300 vs Pregabalin300		Some concerns 🗆	Low risk	No concerns	Some concerns 🗆	No concerns	No concerns	Low
Gabapentin600 vs Gabapentin800		No concerns	Low risk	No concerns	Months summand	No concerns	No concerns	Low
Gabapentin600 vs Pregabalin150	(2)	Some concerns	Low risk	No concerns	Major someonid 1	No concerns	No concerns	Very low
Gabapentin600 vs Pregabalin75	-	Some concerns	Low risk	No concerns	Miller senter mat.□	No concerns	No concerns	Very low
Gabapentin800 vs Gabapentin900	(27)	Some concerns 🗆	Low risk	No concerns	Rapir-samenni D	No concerns	No concerns	Very low
Gabapentin800 vs Pregabalin150	(25)	No concerns	Low risk	No concerns	Water-someone	No concerns	No concerns	Low
Gabapentin800 vs Pregabalin300	(**)	No concerns	Low risk		Autor sometror •	No concerns	No concerns	Low
Gabapentin800 vs Pregabalin75	100	No concerns	Lowrisk		Manusconsum.	No concerns	No concerns	Low
Gabapentin900 vs Pregabalin150		Some concerns	Lowrisk		Manusconsum (Cal	No concerns	No concerns	Very low
Gabapentin900 vs Pregabalin300	-	Some concerns	Low risk	No concerns	(Marter recomment of the	No concerns	No concerns	Very low
Gabapentin900 vs Pregabalin75	-	Some concerns	Low risk	No concerns	Manarasanan na 🗆	No concerns	No concerns	Very low
Pregabalin150 vs Pregabalin300	-	Some concerns	Low risk	No concerns	Some concerns	Some concerns 🗆	No concerns	Low
Pregabalin150 vs Pregabalin75		Some concerns	Low risk	No concerns	Wagair sumadime	No concerns	No concerns	Very low
Pregabalin300 vs Pregabalin75	127	Some concerns	Low risk	No cancerns	Wajar sancana 🗆	No concerns	No concerns	Very low

@ 2023 Tsai SHL et al.  $\emph{JAMA Network Open}.$ 

eFigure 9E CINeMA for Dizziness

Comparison	Number of Studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
			Mixed evi	dence				
Gabapentin1200 vs Gabapentin600	1	Some concerns	Low risk	No concerns	With the second of the	No concerns	No concerns	Very low 🗸
Gabapentin1200 vs Gabapentin900	1	Some concerns	Low risk	No concerns	Waling representation.	No concerns	No concerns	Very low 💙
Gabapentin1200 vs Placebo	3	Some concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Low
Gabapentin1200 vs Pregabalin300	1	Some concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Low
Gabapentin300 vs Placebo	1	No concerns	Low risk	No concerns	liman sommers	No concerns	No concerns	Low
Gabapentin600 vs Gabapentin900	1	Some concerns	Low risk		MSper-content	No concerns	No concerns	Very low 💙
Gabapentin600 vs Placebo	3	No concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Moderate <b>∨</b>
Gabapentin600 vs Pregabalin300	1	Some concerns	Low risk	No concerns	Some concerns	No concerns	No concerns	Low
Gabapentin900 vs Placebo	1	Some concerns	Low risk	No concerns	dundaya episacean ad ■	No concerns	No concerns	Very low 💙
Placebo vs Pregabalin150	2	Some concerns	Low risk	No concerns	Amalogic - District (CAS)	No concerns	No concerns	Very low 🗸
Placebo vs Pregabalin300	5	Some concerns	Low risk	No concerns	No concerns	No concerns	No concerns	Moderate <b>▼</b>
Placebo vs Pregabalin75	2	No concerns	Low risk	No concerns	Some concerns 🗆	Some concerns 🗆	No concerns	Moderate ✔
Pregabalin150 vs Pregabalin75	1	No concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Moderate <b>∨</b>

		Indirect evid	dence				
Gabapentin1200 vs Gabapentin300	 No concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Very l
Gabapentin1200 vs Pregabalin150	 Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very l
Gabapentin1200 vs Pregabalin75	 No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low
abapentin 300 vs Gabapentin 600	 No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low
Sabapentin300 vs Gabapentin900	 Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very l
abapentin300 vs Pregabalin150	 No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
abapentin300 vs Pregabalin300	 No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low
abapentin300 vs Pregabalin75	 No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low
abapentin600 vs Pregabalin150	 Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very l
abapentin600 vs Pregabalin75	 No concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Gabapentin900 vs Pregabalin150	 Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very lo
abapentin900 vs Pregabalin300	 Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very lo
Sabapentin900 vs Pregabalin75	 Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very lo
regabalin150 vs Pregabalin300	 Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Very lo
Pregabalin300 vs Pregabalin75	 No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low

### eTable 1. Electronic Database Search Strategy

#### **OVID**

Database(s): Ovid MEDLINE(R) 1946 to Present and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) Daily, EBM Reviews - Cochrane Central Register of Controlled Trials July 2021, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to August 25, 2021, Embase 1974 to 2021 August 27

Search Strategy: **Searches** exp Spinal Fusion/ 1 2 exp Spine/su ((spine or spinal or lumbar or lumbosacral or cervico\* or cervical or thoracic or thoracolumbar or occipitocervical or "occipito-cervical" or occipitalcervical or "occipital-cervical" or atlantoaxial or "atlanto-axial" or occipitoatlantoaxial or "occipoto-atlantoaxial" or "craniovertebral junction" or subluxation or vertebr\* or intervertebral or disc or discs or disks or sacral or sacrum or "trans-sacr\*") adj10 (fusion\* or fused or fusing or fixation or decompression or surg\* or operat\* or arthrodesis or reconstruct\*)).ti,ab,hw,kw. (discectom\* or diskectom\* or laminectomy or spondylosyndesis).ti,ab,hw,kw. 5 exp Decompression, Surgical/ spinal cord decompression/ 6 7 exp Diskectomy/ Pedicle Screws/ or screw\*.ti. 8 9 or/1-810 | Pregabalin/ 11 (pregabalin or lyrica).mp. 12 10 or 11 13 exp Pain, Postoperative/ pain.ti. or (pain adj7 (after\* or post\* or surg\* or operat\*)).ti,ab. 15 | 13 or 14 16 9 and 12 and 15 (conference abstract or conference review or editorial or erratum or note or addresses or autobiography or bibliography or biography or blogs or comment or dictionary or directory or interactive tutorial or interview or lectures or legal cases or legislation or 17 news or newspaper article or patient education handout or periodical index or portraits or published erratum or video-audio media or webcasts).mp. or conference abstract.st. 18 16 not 17 (exp animals/ or exp nonhuman/) not exp humans/ ((alpaca or alpacas or amphibian or amphibians or animal or animals or antelope or armadillo or armadillos or avian or baboon or baboons or beagle or beagles or bee or bees or bird or birds or bison or bovine or buffalo or buffalos or "c elegans" or "Caenorhabditis elegans" or camel or camels or canine or canines or carp or cats or

cattle or chick or chicken or chickens or chicks or chimp or chimpanze or chimpanzees

or chimps or cow or cows or "D melanogaster" or "dairy calf" or "dairy calves" or deer or dog or dogs or donkey or donkeys or drosophila or "Drosophila melanogaster" or duck or duckling or ducklings or ducks or equid or equids or equine or equines or feline or felines or ferret or ferrets or finch or finches or fish or flatworm or flatworms or fox or foxes or frog or frogs or "fruit flies" or "fruit fly" or "G mellonella" or "Galleria mellonella" or geese or gerbil or gerbils or goat or goats or goose or gorilla or gorillas or hamster or hamsters or hare or hares or heifer or heifers or horse or horses or insect or insects or jellyfish or kangaroo or kangaroos or kitten or kittens or lagomorph or lagomorphs or lamb or lambs or llama or llamas or macaque or macaques or macaw or macaws or marmoset or marmosets or mice or minipig or minipigs or mink or minks or monkey or monkeys or mouse or mule or mules or nematode or nematodes or octopus or octopuses or orangutan or "orang-utan" or orangutans or "orang-utans" or oxen or parrot or parrots or pig or pigeon or pigeons or piglet or piglets or pigs or porcine or primate or primates or quail or rabbit or rabbits or rat or rats or reptile or reptiles or rodent or rodents or ruminant or ruminants or salmon or sheep or shrimp or slug or slugs or swine or tamarin or tamarins or toad or toads or trout or urchin or urchins or vole or voles or waxworm or waxworms or worm or worms or xenopus or "zebra fish" or zebrafish) not (human or humans or patient or patients)).ti,ab,hw,kw.

- 21 (rat or rats or mice or mouse or murine or pig or pigs or porcine or swine or dog or dogs).ti.
- 22 or/19-21
- 23 | 18 not 22
- 24 remove duplicates from 23

## **SCOPUS**

1	TITLE-ABS-KEY ( ( spine OR spinal OR lumbar OR lumbosacral OR cervico* OR
	cervical OR thoracic OR thoracolumbar OR occipitocervical OR "occipito-cervical"
	OR occipitalcervical OR "occipital-cervical" OR atlantoaxial OR "atlanto-axial" OR
	occipitoatlantoaxial OR "occipoto-atlantoaxial" OR "craniovertebral junction" OR
	subluxation OR vertebr* OR intervertebral OR disc OR discs OR disk OR disks OR
	sacral OR sacrum OR "trans-sacr*" ) W/8 ( fusion* OR fused OR fusing OR fixation
	OR decompression OR surg* OR operat* OR arthrodesis OR reconstruct*))
2	TITLE-ABS-KEY (pregabalin or lyrica)
3	TITLE (pain) or TITLE-ABS-KEY (pain W/7 (after* or post* or surg* or operat*))
4	1 and 2 and 3
5	4 AND ( LIMIT-TO ( DOCTYPE,"ar" ) ) AND ( LIMIT-TO
	( LANGUAGE, "English" ) )
6	5 not INDEX(embase) OR INDEX(medline) OR PMID(0* OR 1* OR 2* OR 3* OR
	4* OR 5* OR 6* OR 7* OR 8* OR 9*)

eTable 2 Excluded Studies With Reasons

Author	Study Name	Reasons for exclusion
Reuben 2006	The analgesic efficacy of celecoxib, pregabalin, and their combination for spinal fusion surgery	Retracted article
ElShal 2010	Pregabalin versus ketorolac for postoperative analgesia after lumbar laminectomy (a comparative randomized controlled study)	Only abstract available
Yu 2013	Gabapentin and pregabalin in the management of postoperative pain after lumbar spinal surgery: a systematic review and meta-analysis	Wrong study design
Garcia 2013	A multimodal approach for postoperative pain management after lumbar decompression surgery: a prospective, randomized study	Wrong intervention
Dolgun 2014	Gabapentin versus pregabalin in relieving early post-surgical neuropathic pain in patients after lumbar disc herniation surgery: a prospective clinical trial	No accessible data
Lam 2015	Efficacy of pregabalin in acute postoperative pain under different surgical categories a meta-analysis	Wrong study design
Feng 2016	Preoperative single dose of pregabalin alleviates postoperative pain: Systematic review and meta-analysis	Wrong study design
Ko 2016	The effectiveness of oral corticosteroids for management of lumbar radiating pain: randomized, controlled trial study	Wrong population
Canos 2016	Preventive Analgesia with Pregabalin in Neuropathic Pain from "Failed Back Surgery Syndrome": Assessment of Sleep Quality and Disability	No accessible data
Hirai 2016	Pregabalin versus acetaminophen for a treatment of chronic neuropathic pain on extremities after cervical surgery: a prospective randomized, open-label preliminary study	No accessible data
Kim 2016	Preemptive multimodal analgesia for postoperative pain management after lumbar fusion surgery: a randomized controlled trial	Wrong population
Fujita 2016	A randomized placebo-controlled study of preoperative pregabalin for postoperative analgesia in patients with spinal surgery	No accessible data
Liu 2017	A meta-analysis of the preoperative use of gabapentinoids for the treatment of acute postoperative pain following spinal surgery	Wrong study design
Jiang 2017	Preoperative use of pregabalin for acute pain in spine surgery: A meta-analysis of randomized controlled trials	Wrong study design
Pinar 2017	Effects of Addition of Preoperative Intravenous Ibuprofen to Pregabalin on Postoperative Pain in Posterior Lumbar Interbody Fusion Surgery	Wrong intervention
Helenius 2018	Preoperative pregabalin has no effect on intraoperative neurophysiological monitoring in adolescents undergoing posterior spinal fusion for spinal deformities: a double-blind, randomized, placebo-controlled clinical trial	No accessible data
Omara 2019	The Effect Of The Use Of Pre-Emptive Oral Pregabalin On The Postoperative Spinal Analgesia In Patients Presented For Orthopedic Surgeries: Randomized Controlled Trial	Wrong population

McEntarfer 2019	Multimodal Analgesia for Spinal Surgery - What Is the Gold Standard?	Wrong study design
Trzcinski 2019	Use of Gabapentin in Posterior Spinal Fusion is Associated with Decreased Postoperative Pain and Opioid Use in Children and Adolescents	No accessible data
Helenius 2020	Preemptive Pregabalin in Children and Adolescents Undergoing Posterior Instrumented Spinal Fusion: A Double-Blinded, Placebo-Controlled, Randomized Clinical Trial	No accessible data
Ntalouka 2021	Multimodal Analgesia in Spine Surgery: An Umbrella Review	Wrong study design
Helenius 2021	Pregabalin and Persistent Postoperative Pain Following Posterior Spinal Fusion in Children and Adolescents: A Randomized Clinical Trial	No accessible data
Bilgin 2021	Post-operative pain management for single-level lumbar disc herniation surgery: A comparison of betamethasone, ibuprofen, and pregabalin	No accessible data
NCT01168531 2010	The Effect of Pregabalin and Dexamethasone on Acute and Chronic Pain After Lumbar Spinal Surgery	No results posted
NCT02120703 2014	Pregabalin Compared to Gabapentin for Pain Control in Lumbar Disc Surgery	No results posted
TCTR20160729 003	The effect of preopertive pregabalin administration in postoperative pain control after laminectomy and instrumented fusion in degenerative lumbar spine disease: a randomized double-blind placebo controlled study	Only abstract
UMIN000028 475	The efficacy of duloxetine for neuropathic pain a comparison of pregabalin	No results posted
IRCT2017030 132832N1	Evaluation the effect of two different doses of pregabalin before surgery on postoperative pain after lumbar disc surgery	No results posted
IRCT2019071 9044276N1	The comparison of effect of pregabalin and duloxetine on post-op pain	No results posted
Irct201907030 44091N1	Effects of magnesium sulfate and pregabalin on postoperative pain in posterior lumbar spinal fusion surgery	Wrong intervention
ChiCTR20000 35554	The effects of pregabalin versus gabapentin combined with NSIADs on the pain of spinal surgery: a randomized controlled trial	No results posted
ChiCTR20000 31236	Effect of local infiltration using ropivacaine combined with celebrex and pregabalin on the pain control of spinal surgery	Wrong intervention
ChiCTR21000 42109	Clinical randomized controlled trial of multimodal analgesia (MMA) and patient controlled analgesia (PCA) in Oblique Lumbar Interbody Fusion	Wrong intervention

eTable 3 Descriptions and Demo of the Included Studies

Study (Author, year)	Preexisting neuropathic pain	NSAID use before study	Gabapentinoid use before study	Duration of gabapentinoid use for study	Postoperative VAS assessment timing (hrs)	Postoperative opioid consumption recording timing (hrs)	Postoperative Complication assessment timing(hrs)	Comorbidities	Co- medications	Other outcomes
Pandey et al, 2004	Not mentioned	No (within 48 hrs before surgery)	Not mentioned	2 hrs before surgery	*0-6,6-12, 12- 18, 18-24	*Within 24	*Within 24	NA	NA	Fatigue, light headedness
Turan et al, 2004	Not mentioned	No	No	1 hr before surgery	*1,2,4,6,12,24	1,2,4,6,12,24,*during hospitalization	*Within 24	NA	NA	Somnolence, diarrhea, pruritis, urinary retention, constipation
Pandey et al, 2005	Yes	No (within 24 hrs before surgery)	Not mentioned	2 hrs before surgery	*6,12,18,24	*Within 24	*Within 24	NA	NA	Respiratory depression, light headedness, lack of concentration, feeling on a "high"
Radhakrishnan et al, 2005	Not mentioned	No (within 24 hrs before surgery)	Not mentioned	at night before surgery and 2hrs before surgery	*2,4,6,8	*>8	*during hospitalization	NA	NA	Urinary retention, dry mouth, somnolence, pruritis, headache
Burke et al, 2010	Yes	Not mentioned	Not mentioned	1.5 hr before surgery, 12	*24	Not mentioned	*24	Smoker	Paracetamol, diclofenac, bupivacaine	McGill pain questionnaire, Roland Morris

<sup>© 2023</sup> Tsai SHL et al. JAMA Network Open.

				and 24 hrs after surgery						disability questionnaire. Prolo score, Short Form 36
Hegarty et al, 2011	Yes	Yes, paracetamol 1000 mg every 6 hours	No (within 2 weeks before surgery)	1 hr before surgery	4,8,12,24	Within 24	*Within 24	NA	Diclofenac	Somnolence, lightheadedness, visual disturbance
Khan et al, 2011	Not mentioned	No (within 24 hrs before surgery)	No (within 24 hrs before surgery)	2 hrs before surgery	*0-4,4-8,8- 12,12-24	*Within 24	*during hospitalization	NA	NA	Drowsiness
Kim et al, 2011	Not mentioned	No (within 48rs before surgery)	No (within 48rs before surgery)	1 hr before surgery and 12 hrs after surgery	*1-6,6-24,24-48	1-6,6-24,-24-48	*during hospitalization	NA	NA	Incidence of pain rescues, satisfaction score, sedation, headache, blurred vision
Spreng et al, 2011	Not mentioned	Yes, paracetamol 1000 mg for weight < 60kg; 1500 mg for weight >60 kg	Not mentioned	1 hr before surgery	0.5,1,2,3,4,24	0.5,1,2,3,4,24	*Within 24	NA	NA	Sedation, pruritus, urinary retention, respiratory depression, headache
Ozgencil et al, 2011	Not mentioned	No	No	2 hrs before surgery, 10 and 22 hrs after surgery	*1,2,4,6,12,24	1,2,4,6,12, *within 24	*during hospitalization	NA	NA	Satisfaction with pain medication, numeric sedation score, somnolence,

<sup>© 2023</sup> Tsai SHL et al. JAMA Network Open.

	1		T	1	T	T	1	T	ı	1
										headache,
										blurred vision,
										urinary
										retention,
										pruritus,
										shivering
										Pruritus,
										sedation,
										respiratory
										depression,
				1 hr before						hypotension,
Gianesello et	Not	Not		surgery and	1,4,8,12,24,48,		*during			headache,
al,	mentioned	mentioned	No	twice a day	3 months, 1year	1,4,8,12,24,*48	hospitalization	NA	NA	constipation,
2012				after surgery	, , , , , , , , , , , , , , , , , , ,					diarrhea,
				for 2 days						peripheral
										edema, dry
										mouth, blurred
										vision, quality
										of Life
				1hr before						Incidence of
Choi et al,		Not		surgery and			*0-12,12-			pain rescue,
2013	Yes	mentioned	No	every 12 hrs	*12,24,48,72	Not mentioned	24,24-48,48-	NA	NA	back pain, leg
				after surgery			72			pain, daily
				(total 8 doses)						activities
Kumar et al,	Not	Not		1hr before			*during			Anxiety score,
2013	mentioned	mentioned	No	surgery	*1,2,4,6	*6	hospitalization	NA	Diclofenac	sedation score,
				2 3			1			drowsiness
				1hr before	3,6,12,24,36,48,			Diabetes,		Prolo score,
Khurana et al,	Yes	Not	No	surgery and	72,7days,	Not mentioned	*during	hypertension,	NA	Oswestry
2014 Yes		mentioned		every 8 hours	21days,3		hospitalization	alcoholic,	NA	disability index
				J 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	months			smoker, others		score, sedation,

<sup>© 2023</sup> Tsai SHL et al. JAMA Network Open.

	T	T		for 7 days						vertigo,
				after surgery						numbness
Zarei et al, 2016	Yes	Yes	No(within 2 weeks before surgery)	8hrs before surgery and every 12 hours for 14 days after surgery for 2 days or14 days	*4,8,12,24	Not mentioned	Within 24	Smoker	NA	NA
Vasigh et al, 2016	Yes	No	Not mentioned	2hrs before surgery and 6 hours after surgery	*2,4,6,8,12,24	*Not mentioned	*during hospitalization	NA	NA	Shivering, drowsiness, pruritus, urinary retention, headache
Qadeer et al, 2017	Not mentioned	Not mentioned	No	twice daily for a week before surgery	*24, 1 week	Not mentioned	Not mentioned	Hypertension , diabetes, COPD, others	NA	NA
Yadav et al, 2018	Not mentioned	No (within 24hrs before surgery)	No	2hrs before surgery	Not mentioned	*during hospitalization	Not mentioned	NA	NA	Mean arterial blood pressure, heart rate, bispectral index
Urban et al, 2018	Yes	Not mentioned	No	1hr before surgery and twice daily for 14 days after surgery	*24,48,72	0-6,7-12,13-18,19- 24,25-48,49-72	*24,48,72	NA	NA	Sedation, hospital stay
Altiparmak et al, 2018	Not mentioned	No	No	1hr before surgery, 12th and 24th hr after surgery	1 min, 0.5, 1,2,24,48	Not mentioned	*during hospitalization	NA	Paracetamol	Montreal Cognitive Assessment, delay of first

<sup>@</sup> 2023 Tsai SHL et al.  $\emph{JAMA Network Open}.$ 

_			1						•	,
										analgesic
										request,
										incidence of
										pain rescue,
										hypotension,
										bradycardia,
										allergia, itching
										Sedation, time
										to first dose of
Routray et al,	Not	Not	Not mentioned	1hr before	1,2,4,6,8,12,16,	within 24	*during	NA	Paracetamol	rescue
2018	mentioned	mentioned	Not includicu	surgery	20,24	Within 24	hospitalization	IVA	Taracctamor	analgesia,
										incidence of
										pain rescues,
										Dry mouth,
										difficulty in
										urination,
Raja et al,	Not	No(within		4hrs before	4,8,12,16,20,24,	*during	*during		Paracetamol,	constipation,
2019	mentioned	24 hrs before	Not mentioned	surgery	28,32,36,40,44,	hospitalization	hospitalization	NA	ketorolac	hospital stay, -
2017	mentioned	surgery)		surgery	48	nospitanzation	nospitanzation		Retorolae	North American
										Spine Society
										satisfaction
										scale
								Hypertension,		Hospital stay,
								coronary	Acetaminop	time to first
								disease,	hen,	ambulation,
Momon et al,	Not	Not	No (within 48	1 hr before	During		*During	cardiac	nonsteroidal	persistent pain,
2019	mentioned	mentioned	hrs before	surgery	hospitalization,	*within 48	hospitalization	insufficiency,	anti-	pain intensity,
	· · · · · · · · · · · · · · · · · · ·		surgery)		6 months			arteritis,	inflammator	regular opioid
								thromboembol	ol inflammator y drugs	intake,
								ic disease,	7	neuropathic
								sleep apnea,		pain, quality of

<sup>© 2023</sup> Tsai SHL et al. JAMA Network Open.

			T	1	T	T				
								smoker,		first attempt to
								dyspnea,		stand up,
								asthma,		sedation,
								gastroesophag		urinary
								eal disease,		retention,
								viral hepatitis,		hypotension,
								regular		hypertension,
								alcohol intake,		sleep
								diabetes,		disturbance,
								dyslipidemia,		headache,
								hypothyroidis		diarrhea,
								m, allergy,		hyperglycemia,
								cancer,		gastralgia,
								lithiasis,		hyperthermia,
								migraine,		respiratory
								anxiety,		disturbance,
								depression,		radiculopathy
								cerebral		
								disease,		
								infection		
										Recovery
Bala et al,	Not	Not	No	1.5hr before	*1,2,4,6,1,24	*within 24	During	NA	NA	profile, Ramsay
2019	mentioned	mentioned	NO	surgery	1,2,4,0,1,24	Within 24	hospitalization	NA	NA	sedation scale
										score
										Mean arterial
										blood pressure,
Kien et al,	Not	Not	No	2hrs before	*0.25,0.5,1,4,8,	Within 24,*within 48	During	NA	Celecoxib	heart rate,
2019	mentioned	mentioned	INO	surgery	16,24,36,48	within 24, "Within 48	hospitalization	INA	Celecoxid	respiratory rate,
										SpO <sub>2</sub> , sedation
										score, time to
	1	l	l	1	l .	l .			I	

 $<sup>\</sup>odot$  2023 Tsai SHL et al.  $\it JAMA$  Network Open.

										first dose of
										rescue analgesia
										Walking time,
				2hrs before		Not mentioned	*During hospitalization			hospital stay,
Zhang et al,	Not	Not		surgery twice					Celebrex,	fever, infection,
2021	mentioned	mentioned	Not mentioned	daily for 7	*2,12,24,72,120			NA	ropivacaine	urination
2021	mendoned			days after						disorder,
				surgery						secondary
										surgery
				Twice daily on						
Baloch et al,		Not		preoperative				NA	Paracetamol,	Roland-Morris
2021	Yes	mentioned	Not mentioned	day till one	*1 week	Not mentioned	Not mentioned		ketorolac	disability scale
2021		menuonea		week after					Ketorolac	disability scale
				surgery						

NSAIDs: Non-steroidal anti-inflammatory drugs

<sup>\*:</sup> used for further analysis

eTable 4: Assessment of Inconsistency With Design-by-Treatment Interaction Models

	Chi-Square	P value for test of
		global inconsistency
VAS	7.59	0.6684
Opioid Consumption	3.70	0.9883
Nausea	6.69	0.9461
Vomit	7.83	0.8121
Dizziness	2.67	0.9536

eTable 5 Meta-Regression of Covariates for Outcomes

Outcomes	Covariates	P value
	Co-medication	0.6743
VAS	Funding	0.7427
VAS	Postoperative gabapentinoid use	0.3004
	Preexisting neuropathic pain	0.4208
	Co-medication	0.5127
Opioid	Funding	0.9039
Consumption	Postoperative gabapentinoid use	0.5182
	Preexisting neuropathic pain	0.0566
	Co-medication	0.9283
Nausea	Funding	0.0148*
Nausea	Postoperative gabapentinoid use	0.0513
	Preexisting neuropathic pain	0.4762
	Co-medication	0.8106
Vomit	Funding	0.2638
VOIIII	Postoperative gabapentinoid use	0.3476
	Preexisting neuropathic pain	0.6426
	Co-medication	0.7637
Dizziness	Funding	0.9878
DIZZIIICSS	Postoperative gabapentinoid use	0.8308
	Preexisting neuropathic pain	0.7637
*significant differen	ice	L


<sup>© 2023</sup> Tsai SHL et al. JAMA Network Open.

eTable 6 SUCRA, PrBest, and Mean Rank of Different Dosages of Gabapentin and Pregabalin for Patients Undergoing Spinal Surgery.

$\mathbf{A}$				В			
Treatment(Vomit)	SUCRA	PrBest	MeanRank	Treatment(Dizziness)	SUCR A	PrBest	MeanRank
Gabapentin900mg	70.8	35.4	3.3	Gabapentin300mg	77.9	60.6	2.5
Pregabalin150mg	69.9	22.2	3.4	Pregabalin150mg	64.7	17.5	3.5
Gabapentin1200mg	63.0	10.4	4.0	Placebo	63.2	2.7	3.6
Gabapentin600mg	62.4	6.5	4.0	Pregabalin300mg	53.8	2.8	4.2
Pregabalin300mg	49.2	2.1	5.1	Gabapentin900mg	49.1	12.8	4.6
Pregabalin75mg	48.7	5.7	5.1	Gabapentin600mg	34.0	1.3	5.6
Gabapentin800mg	45.3	16.4	5.4	Gabapentin1200mg	30.2	0.6	5.9
Gabapentin300mg	27.1	1.3	6.8	Pregabalin75mg	27.3	1.7	6.1
Placebo	13.5	0.0	7.9				

## Sensitivity analysis for nausea (studies without funding)

eFigure 10: Network Graph for Nausea Without Funding




eFigure 11: Network Meta-Analysis League Tables for Nausea Without Funding

(In the left lower half, odds ratio lower than 1 favor the row-defining treatment)


Pregabalin7 5								
3.00 (0.97,9.31)	Pregabalin300							
3.10 (0.90,10.64)	1.03 (0.32,3.36)	Pregabalin150						
1.72 (0.71,4.20)	0.57 (0.28,1.16)	0.56 (0.21,1.44)	Placebo					
2.05	0.68	0.66	1.19	Gabapentin90				
(0.42,10.02)	(0.16,2.90)	(0.13,3.37)	(0.32,4.47)	0				
1.72	0.57	0.56	1.00	0.84	Gabapentin80			
(0.37,8.10)	(0.14,2.44)	(0.11,2.71)	(0.28,3.54)	(0.13,5.25)	0			
1.58	0.53	0.51	0.92	0.77	0.92	Gabapentin60		
(0.42,5.97)	(0.17,1.61)	(0.13,2.02)	(0.34,2.48)	(0.19,3.07)	(0.18,4.59)	0		
2.41	0.80	0.78	1.40	1.18	1.40	1.53	Gabapentin30	
(0.72,8.09)	(0.23,2.83)	(0.19,3.17)	(0.48,4.03)	(0.22,6.15)	(0.27,7.28)	(0.37,6.33)	0	
1.63	0.54	0.52	0.94	0.79	0.94	1.03	0.68	Gabapentin120
(0.52,5.07)	(0.22,1.31)	(0.16,1.72)	(0.46,1.93)	(0.21,3.07)	(0.22,4.04)	(0.35,3.05)	(0.19,2.36)	0

<sup>© 2023</sup> Tsai SHL et al. JAMA Network Open.

eFigure 12: Rank Plot for Nausea Without Funding




eFigure 13: Forest Plot of Network Meta-Analysis Results for Nausea Without Funding (Placebo as Reference)




eFigure 14: Forest Plot of Pairwise Comparison for Nausea Without Funding


(A: placebo, B: Gabapentin 300mg, C: Gabapentin 600 mg, D: Gabapentin 800mg, E: Gabapentin 900mg, F: Gabapentin 1200mg, G: pregabalin 75mg, H: pregabalin 150mg, I: pregabalin 300mg)



eFigure 15: Publication Bias: Funnel Plot for Nausea Without Funding



eFigure 16: Publication Bias: The Egger Test for Nausea Without Funding



© 2023 Tsai SHL et al. JAMA Network Open.

eFigure 17: CINeMA for Nausea Without Funding

Comparison	Number of Studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Mixed evidence								
Gabapentin1200 vs Gabapentin300	1	Some concerns	Low risk	No concerns	Major concerns □	No concerns	No concerns	Very low 🗸
Gabapentin1200 vs Gabapentin600	2	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Very low 🗸
Gabapentin1200 vs Gabapentin900	2	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Very low 🗸
Gabapentin1200 vs Placebo	4	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Very low 🗸
Gabapentin1200 vs Pregabalin300	1	Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very low 🗸
Gabapentin300 vs Gabapentin600	1	Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very low 🗸
Gabapentin300 vs Gabapentin900	1	Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very low 🗸
Gabapentin300 vs Placebo	3	No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low 🗸
Gabapentin300 vs Pregabalin75	1	Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very low 🗸
Gabapentin600 vs Gabapentin900	2	Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very low 🗸
Gabapentin600 vs Placebo	3	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Very low 🗸
Gabapentin600 vs Pregabalin300	1	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Very low 🗸
Gabapentin800 vs Placebo	1	No concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Low 🗸
Gabapentin900 vs Placebo	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Very low 🗸
Placebo vs Pregabalin150	3	Some concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Very low 🗸
Placebo vs Pregabalin300	4	No concerns	Low risk	No concerns	Major concerns 🗖	No concerns	No concerns	Low 🗸
Placebo vs Pregabalin75	3	No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low 🗸
Pregabalin150 vs Pregabalin75	1	No concerns	Low risk	No concerns	Major concerns 🗆	No concerns	No concerns	Low

Indirect evidence							
Gabapentin1200 vs Gabapentin800	No concerns	Low risk	No concerns	Major concerns 🗆	No concerns No concerns	Low 🗸	
Gabapentin1200 vs Pregabalin150	Some concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Very low 🕶	
Gabapentin1200 vs Pregabalin75	No concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Low 🗸	
Gabapentin300 vs Gabapentin800	No concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Low 🗸	
Gabapentin300 vs Pregabalin150	No concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Low 🗸	
Gabapentin300 vs Pregabalin300	No concerns	Low risk	No concerns	Major concerns 🗖	No concerns No concerns	Low 🗸	
Gabapentin600 vs Gabapentin800	Some concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Very low 💙	
Gabapentin600 vs Pregabalin150	Some concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Very low 💙	
Gabapentin600 vs Pregabalin75	Some concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Very low 💙	
Gabapentin800 vs Gabapentin900	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns No concerns	Very low 💙	
Gabapentin800 vs Pregabalin150	No concerns	Low risk	No concerns	Major concerns 🗖	No concerns No concerns	Low 🗸	
Gabapentin800 vs Pregabalin300	No concerns	Low risk	No concerns	Major concerns 🗖	No concerns No concerns	Low 🗸	
Gabapentin800 vs Pregabalin75	No concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Low 🗸	
Gabapentin900 vs Pregabalin150	Some concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Very low 💙	
Gabapentin900 vs Pregabalin300	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns No concerns	Very low 💙	
Gabapentin900 vs Pregabalin75	Some concerns	Low risk	No concerns	Major concerns 🗖	No concerns No concerns	Very low 💙	
Pregabalin150 vs Pregabalin300	Some concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Very low 🗸	
Pregabalin300 vs Pregabalin75	No concerns	Low risk	No concerns	Major concerns	No concerns No concerns	Low 🗸	

eTable 7. SUCRA, PrBest, and Mean Rank of Different Dosages of Gabapentin and Pregabalin for Patients Undergoing Spinal Surgery.

Treatment (Nausea without funding)	SUCRA	PrBest	MeanRank
Pregabalin300mg	78.4	24.3	2.7
Pregabalin150mg	76.6	31.4	2.9
Gabapentin300mg	64.6	18.3	3.8
Gabapentin900mg	52.7	12.9	4.8
Gabapentin800mg	45.2	9.9	5.4
Placebo	41.6	0.0	5.7
Gabapentin600mg	38.5	2.3	5.9
Gabapentin1200mg	38.0	0.9	6.0
Pregabalin75mg	14.5	0.0	7.8

eTable 8: Assessment of Inconsistency With Design-by-Treatment Interaction Models

	Chi-Square	P value for test of
		global inconsistency
VAS	7.53	0.8728

## **eReferences**

- 1. Myles, P. S. *et al.* Measuring acute postoperative pain using the visual analog scale: the minimal clinically important difference and patient acceptable symptom state. *Br. J. Anaesth.* **118**, 424–429 (2017).
- 2. <u>Papakonstantinou, T., Nikolakopoulou, A., Higgins, J. P. T., Egger, M. & Salanti, G. CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. *Campbell Syst. Rev.* **16**, (2020).</u>